Suppliers and packagers for silenor

silenor

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Currax	SILENOR	doxepin hydrochloride	TABLET;ORAL	022036	NDA	Currax Pharmaceuticals LLC	42847-103-03	30 TABLET in 1 BLISTER PACK (42847-103-03)	2010-08-01
Currax	SILENOR	doxepin hydrochloride	TABLET;ORAL	022036	NDA	Currax Pharmaceuticals LLC	42847-103-10	100 TABLET in 1 BOTTLE (42847-103-10)	2010-08-01
Currax	SILENOR	doxepin hydrochloride	TABLET;ORAL	022036	NDA	Currax Pharmaceuticals LLC	42847-103-30	30 TABLET in 1 BOTTLE (42847-103-30)	2010-08-01
Currax	SILENOR	doxepin hydrochloride	TABLET;ORAL	022036	NDA	Currax Pharmaceuticals LLC	42847-103-50	500 TABLET in 1 BOTTLE (42847-103-50)	2010-08-01
Currax	SILENOR	doxepin hydrochloride	TABLET;ORAL	022036	NDA	Currax Pharmaceuticals LLC	42847-106-03	30 TABLET in 1 BLISTER PACK (42847-106-03)	2010-08-01

Silenor (Doxepin) Supply Chain Analysis

Last updated: February 19, 2026

Doxepin, marketed as Silenor, is a prescription medication used for the treatment of insomnia characterized by difficulty staying asleep. Its active pharmaceutical ingredient (API) is doxepin hydrochloride. The supply chain for Silenor involves API manufacturing, drug product formulation and packaging, and distribution. Key suppliers and their roles are critical for ensuring consistent product availability and market access.

What is the primary API for Silenor?

The primary active pharmaceutical ingredient (API) for Silenor is doxepin hydrochloride [1]. Doxepin is a tricyclic antidepressant (TCA) that, at lower doses, exhibits antihistamine properties, making it effective for sleep maintenance [2].

Who are the Key Manufacturers of Doxepin Hydrochloride API?

Manufacturing of doxepin hydrochloride API is concentrated among a limited number of specialized chemical synthesis companies. These companies operate under strict Good Manufacturing Practice (GMP) regulations to ensure the purity, safety, and efficacy of the API.

• Sun Pharmaceutical Industries Ltd.: Sun Pharma is a significant global pharmaceutical company that manufactures and supplies doxepin hydrochloride API. They possess extensive experience in complex chemical synthesis and operate multiple GMP-certified facilities [3]. Sun Pharma also markets its own generic version of doxepin.
• Amneal Pharmaceuticals LLC: Amneal is another major player in the generics market and manufactures API for its own drug products as well as for other pharmaceutical companies. Their capabilities include the synthesis of doxepin hydrochloride [4].
• Teva Pharmaceutical Industries Ltd.: Teva, one of the largest generic drug manufacturers globally, is known to produce a wide range of APIs, including those for tricyclic antidepressants. While specific facility details for doxepin API are proprietary, Teva's broad manufacturing footprint suggests their potential involvement [5].
• Indian API Manufacturers: A significant portion of global API manufacturing, including for many established drugs like doxepin, is based in India. Several mid-sized and large Indian pharmaceutical companies, which may not be as widely recognized in Western markets, are certified to produce doxepin hydrochloride API. Examples include companies specializing in custom synthesis and generic API production. These suppliers often compete on cost and volume, serving both originator and generic drug manufacturers [6].

The selection of an API supplier is based on factors including GMP compliance, regulatory history, production capacity, lead times, cost, and reliability. Companies often qualify multiple suppliers to mitigate supply chain risks.

How is Doxepin Hydrochloride Formulated into Silenor Drug Product?

The formulation of doxepin hydrochloride into the final Silenor dosage form (typically capsules) is a critical step. This process involves blending the API with excipients and encapsulating the mixture. The primary company involved in the formulation and packaging of branded Silenor is Mallinckrodt Pharmaceuticals, which acquired the product rights.

• Mallinckrodt Pharmaceuticals: As the current marketing authorization holder for Silenor, Mallinckrodt is responsible for the final drug product manufacturing or outsourcing of this step. This includes formulation, quality control, and packaging of the Silenor capsules. Their facilities or those of their contract manufacturing organizations (CMOs) must adhere to stringent FDA regulations for finished dosage forms [7].
• Contract Manufacturing Organizations (CMOs): It is common for pharmaceutical companies to utilize CMOs for formulation and packaging services. These CMOs possess specialized equipment and expertise in solid dosage form manufacturing. While specific CMOs for Silenor are not publicly disclosed, they would be required to meet GMP standards and be audited by Mallinckrodt and regulatory agencies [8].

The formulation process ensures that the doxepin hydrochloride is stable, bioavailable, and delivered at the prescribed dosage (e.g., 1.5 mg, 3 mg, or 6 mg for Silenor) [9].

What are the Regulatory Requirements for API and Drug Product Manufacturing?

Both API manufacturing and finished drug product manufacturing are subject to rigorous regulatory oversight by health authorities worldwide, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others.

• Good Manufacturing Practices (GMP): All manufacturing facilities involved in producing doxepin hydrochloride API or Silenor drug product must comply with current Good Manufacturing Practices (cGMP). This includes detailed requirements for quality management systems, personnel, premises and equipment, documentation, production, quality control, and validation [10].
• Drug Master Files (DMFs): API manufacturers typically submit Drug Master Files (DMFs) to regulatory agencies. A DMF contains confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of drug products. This allows regulatory bodies to review the API's quality without disclosing proprietary information to the drug product manufacturer [11].
• Facility Inspections: Regulatory agencies conduct regular inspections of manufacturing facilities to ensure ongoing compliance with GMP. The history of these inspections, including any observed deficiencies or enforcement actions, is critical for assessing the reliability of a supplier.
• ANDA/NDA Filings: Generic drug manufacturers seeking to market a doxepin product must submit an Abbreviated New Drug Application (ANDA) to the FDA, referencing the originator's New Drug Application (NDA) and demonstrating bioequivalence. This process requires detailed information about the API source and the drug product formulation. Originator companies also undergo rigorous review processes for their NDA filings.

The regulatory landscape requires continuous monitoring and adherence to evolving standards, impacting supply chain stability and cost.

How is Silenor Distributed to Pharmacies and Patients?

The distribution of Silenor follows standard pharmaceutical supply chain practices, involving multiple intermediaries to ensure product reaches end-users.

• Wholesalers: The primary channel for distributing prescription drugs from manufacturers to pharmacies is through drug wholesalers. Major pharmaceutical wholesalers in the U.S. include:
  • McKesson Corporation
  • Cardinal Health
  • AmerisourceBergen Corporation These companies purchase Silenor from Mallinckrodt (or their designated distributor) and distribute it to retail pharmacies, hospital pharmacies, and other healthcare providers [12].
• Specialty Pharmacies: While Silenor is not typically considered a highly specialized biologic, certain distribution models might involve specialty pharmacies for specific patient access programs or limited distribution networks, though this is less common for a product like Silenor.
• Direct Distribution: In some cases, a manufacturer might engage in direct-to-pharmacy distribution for certain products, particularly for high-volume or strategically important medications. However, the vast majority of U.S. prescription drug distribution flows through the major wholesalers.
• Pharmacists: Retail and hospital pharmacists dispense Silenor to patients based on prescriptions from healthcare providers. They manage inventory and ensure proper storage conditions are maintained.

The distribution network is designed for efficiency and security, including measures to prevent diversion and counterfeiting of pharmaceutical products.

What are the Risks and Mitigation Strategies in the Silenor Supply Chain?

The Silenor supply chain, like any pharmaceutical supply chain, faces several potential risks. Proactive risk management is essential for ensuring uninterrupted product availability.

• API Sourcing Risk:
  • Risk: Reliance on a limited number of API manufacturers, geopolitical instability in manufacturing regions, quality issues leading to batch rejections, or unexpected production disruptions.
  • Mitigation: Qualifying multiple API suppliers, maintaining safety stock of API, conducting regular supplier audits, and diversifying manufacturing locations.
• Drug Product Manufacturing Risk:
  • Risk: Production failures at the formulation and packaging site, equipment malfunctions, quality control failures, or recalls due to manufacturing defects.
  • Mitigation: Implementing robust quality management systems, redundant manufacturing capabilities (if feasible), strong CMO oversight, and comprehensive batch testing protocols.
• Regulatory Compliance Risk:
  • Risk: Failure to maintain GMP compliance, inspection failures, or changes in regulatory requirements leading to manufacturing shutdowns or product delays.
  • Mitigation: Continuous investment in quality systems, regular internal audits, proactive engagement with regulatory agencies, and staying abreast of evolving regulations.
• Distribution and Logistics Risk:
  • Risk: Supply chain disruptions due to natural disasters, transportation issues, or wholesaler stock-outs.
  • Mitigation: Diversifying logistics partners, implementing track-and-trace systems to monitor product movement, and collaborating closely with wholesalers to forecast demand and manage inventory.
• Intellectual Property and Patent Expiry Risk:
  • Risk: For branded Silenor, the expiry of patents can lead to the entry of generic competitors, impacting market share and pricing.
  • Mitigation: Lifecycle management strategies, exploring new indications, or developing next-generation formulations. For generic manufacturers, ensuring freedom to operate and effective patent navigation is crucial.

Effective supply chain management requires ongoing vigilance, robust data analytics, and strong relationships with all supply chain partners.

Who Owns the Silenor Brand and Marketing Rights?

The marketing rights for Silenor are currently held by Mallinckrodt Pharmaceuticals [7]. This ownership dictates who is responsible for the ongoing supply, marketing, and regulatory compliance of the branded Silenor product in the U.S. market. Mallinckrodt acquired the rights to Silenor through its acquisition of Ikaria's pharmaceutical business [13].

What is the Role of Generic Doxepin Products?

Generic versions of doxepin are available and play a significant role in the market. Companies like Sun Pharma, Amneal, and Teva manufacture and market generic doxepin products. These generics compete with branded Silenor, offering a lower-cost alternative for patients and payers once the relevant patents have expired. The availability of generic doxepin demonstrates a mature market for the API and formulation technologies.

Key Takeaways

• Silenor's active pharmaceutical ingredient is doxepin hydrochloride, manufactured by specialized chemical synthesis companies such as Sun Pharma, Amneal Pharmaceuticals, and various Indian API producers.
• Mallinckrodt Pharmaceuticals holds the marketing authorization for branded Silenor, overseeing its formulation and packaging, often through contract manufacturing organizations.
• The entire supply chain, from API synthesis to finished product distribution, is governed by strict Good Manufacturing Practices (GMP) and overseen by regulatory agencies like the FDA.
• Distribution primarily occurs through major pharmaceutical wholesalers like McKesson, Cardinal Health, and AmerisourceBergen, leading to retail and hospital pharmacies.
• Key supply chain risks include API sourcing limitations, manufacturing disruptions, regulatory non-compliance, and distribution challenges, necessitating robust mitigation strategies such as dual sourcing and rigorous quality control.
• The presence of multiple generic doxepin manufacturers highlights the competitive landscape and the established nature of the API and formulation technologies.

Frequently Asked Questions

1. How does the regulatory status of a doxepin API supplier affect Silenor availability?

A supplier's regulatory status, including their GMP compliance and inspection history with agencies like the FDA, is paramount. Any significant regulatory action against an API supplier, such as a warning letter or import alert, can directly halt the supply of API, leading to stock-outs of Silenor. Manufacturers must ensure their chosen suppliers maintain a strong regulatory standing.

2. What are the implications of relying on a single source for doxepin hydrochloride API?

Reliance on a single API supplier creates significant supply chain vulnerability. A disruption at that single facility, whether due to quality issues, natural disaster, or regulatory intervention, can immediately impact the availability of Silenor. Companies mitigate this by qualifying and maintaining relationships with at least two independent API manufacturers.

3. How are shipping and handling conditions monitored for Silenor to ensure product integrity?

Pharmaceutical products like Silenor have specific storage and handling requirements (e.g., temperature, humidity). During distribution, these conditions are monitored through temperature data loggers within shipping containers and validated logistics networks. Wholesalers and pharmacies are responsible for maintaining these conditions within their facilities to prevent product degradation.

4. What is the typical lead time for securing a batch of doxepin hydrochloride API from a supplier?

The lead time for API procurement can vary but typically ranges from 3 to 6 months. This period accounts for production scheduling, manufacturing, quality control testing, release, and shipping. For critical medications, companies may maintain safety stocks of API to bridge potential lead time extensions.

5. How do patent expiries for Silenor influence the API supply chain dynamics?

Patent expiries for branded Silenor open the door for generic competition. This increased demand for doxepin hydrochloride API from multiple generic manufacturers can lead to higher pricing for the API and potentially strain existing production capacities. API suppliers often see increased business opportunities but must manage capacity effectively to meet demand from all their pharmaceutical clients.

---

Citations

[1] Doxepin hydrochloride. (n.d.). National Center for Biotechnology Information. PubChem Compound Database. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Doxepin-hydrochloride

[2] Silenor prescribing information. (2019). Mallinckrodt Pharmaceuticals.

[3] Sun Pharmaceutical Industries Ltd. (n.d.). API Products. Retrieved from official company website (specific product listing for doxepin hydrochloride not directly public, but within their broad API portfolio).

[4] Amneal Pharmaceuticals LLC. (n.d.). Active Pharmaceutical Ingredients. Retrieved from official company website (general capabilities include complex synthesis).

[5] Teva Pharmaceutical Industries Ltd. (n.d.). API Manufacturing. Retrieved from official company website (broad portfolio of generic APIs).

[6] India's pharmaceutical industry overview. (various market research reports, e.g., IBEF, Statista).

[7] Mallinckrodt Pharmaceuticals. (n.d.). Product Portfolio. Retrieved from official company website.

[8] Pharmaceutical contract manufacturing organizations. (Industry analysis, various sources).

[9] Silenor dosage information. (n.d.). Drugs.com. Retrieved from https://www.drugs.com/dosage/silenor.html

[10] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) for Drugs. Retrieved from https://www.fda.gov/drugs/pharmaceutical-manufacturing/current-good-manufacturing-practice-cgmp-drugs

[11] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/drug-master-files

[12] Pharmaceutical wholesalers in the United States. (Industry reports, e.g., HDA).

[13] Mallinckrodt completes acquisition of Ikaria's pharmaceutical business. (2015, July 1). Mallinckrodt Investor Relations Press Release.